Navigation Links
MAP Pharmaceuticals Reports 2008 Fourth Quarter and Year End Financial Results
Date:3/2/2009

MOUNTAIN VIEW, Calif., March 2 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced financial results for the fourth quarter and year ended December 31, 2008.

The net loss for the fourth quarter ended December 31, 2008 was $21.8 million compared with $14.9 million during the same period in 2007. The net loss for the year ended December 31, 2008 was $72.9 million compared with $40.1 million for the year ended December 31, 2007.

MAP Pharmaceuticals had $44.7 million in cash, cash equivalents and short-term investments as of December 31, 2008. Subsequent to December 31, 2008, the company received a $40 million upfront payment from AstraZeneca pursuant to the worldwide Unit Dose Budesonide, UDB, collaboration signed on December 19, 2008.

"Despite the recently announced results from our UDB clinical trial, MAP Pharmaceuticals made progress in a number of areas in 2008. Moving into 2009, we have a strong balance sheet, a robust pipeline and significant upcoming milestones, including efficacy results from our first Phase 3 clinical trial of MAP0004 for the potential treatment of migraine," said Timothy S. Nelson, President and Chief Executive Officer of MAP Pharmaceuticals.

2008 and 2009 Year to Date Key Developments

Unit Dose Budesonide

  • Initiated our first Phase 3 clinical trial of UDB, for the potential treatment of asthma in children, and completed patient enrollment. On February 23, 2009 announced top-line results indicating that this trial did not meet its primary endpoints.
  • Entered into an exclusive worldwide collaboration with AstraZeneca to develop and commercialize UDB.
  • Announced positive results from a pharmacokinetic clinical trial of UDB, demonstrating lower syste
    '/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Transcept Pharmaceuticals to Present at Two Upcoming Conferences
2. Endo Pharmaceuticals Announces Extension of its Tender Offer for Shares of Indevus Pharmaceuticals
3. Alexza Pharmaceuticals Promotes Peter D. Noymer, PhD to Vice President, Product R&D
4. Alseres Pharmaceuticals, Inc. Announces $200,000 Financing
5. Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results
6. Endo Pharmaceuticals Returns Product Rights to TRANSDUR(TM)-Sufentanil to DURECT
7. Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results and Highlights
8. Arbor Pharmaceuticals Announces the Launch of XYLAREX(TM) - A New Nonantibiotic Product for the Dietary Management of Recurrent Ear Infections in Children
9. Endo Pharmaceuticals Appoints William Montague to Board of Directors
10. Access Pharmaceuticals Closes Acquisition of MacroChem Corp.
11. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... 18, 2013 -- Lauren Sciences, a privately-held biotechnology ... platform technology, announced today that it was independently ... with its V-Smart Platform, and selected as a ... Group. , The report, " Early ... Emerging Companies ," features companies MCD Group independently ...
(Date:6/18/2013)... are more likely to keep their scheduled medical appointments ... feel their physician listens, explains things clearly and knows ... Johns Hopkins research suggests. , "If people feel their ... feel that doctor has their best interests at heart ... says study leader Tabor E. Flickinger, M.D., M.P.H., a ...
(Date:6/18/2013)... Obama officially declared June as Lesbian, Gay, ... despite advances in civil rights, sexual minority ... suicide than their heterosexual peers, according to ... of Missouri psychology graduate student recently published ... minority youth, which could help improve psychological ...
(Date:6/18/2013)... FDA to support the need for a blood test ... University of Rochester Medical Center just added significant evidence ... that it might be clinically useful to measure two ... M.P.H., an associate professor of Emergency Medicine at URMC, ... combination of two proteins released into the bloodstream after ...
(Date:6/18/2013)... penalties on hospitals with higher-than-expected rates of 30-day ... are evaluating the most accurate methods for tracking ... in the June issue of the Journal ... that the American College of Surgeons National Surgical ... accurate data tracking than another popular database, the ...
Breaking Medicine News(10 mins):Health News:Respect may be the key to stopping patient 'no shows' 2Health News:Sexual minority youth need specialized treatment from therapists 2Health News:ACS NSQIP® data is more accurate than administrative data for tracking 30-day hospital readmissions 2Health News:ACS NSQIP® data is more accurate than administrative data for tracking 30-day hospital readmissions 3Health News:ACS NSQIP® data is more accurate than administrative data for tracking 30-day hospital readmissions 4
... a milestone in the evolution of its pioneering stem ... received a $34.9 million grant from the California Institute ... a regenerative medicine building on its campus. , The ... Rafael Violy, was approved by the UC Regents in ...
... project as innovative in terms of energy efficiency and ... awarded nearly $27 million in funding for a new ... (USC). USC was one of 12 California institutions considered ... million to build stem cell research facilities throughout California. ...
... The University of Alabama at Birmingham (UAB) this ... a speedier cancer radiation therapy. The new technique can ... for selected patients. , Additionally, the new therapy saves ... that are the same or better than other radiotherapy ...
... SAN CARLOS, Calif., May 7 Nektar Therapeutics,(Nasdaq: NKTR ... ended March 31, 2008., Cash, cash equivalents, and short-term ... million at December 31, 2007., Nektar reported a net ... quarter of 2008, compared to a net loss of $25.7 ...
... PHILADELPHIA, May 7 Kappa Alpha Psi Fraternity, Inc.,announced ... the St.,Jude Children,s Research Hospital and their work to ... the St. Jude Children,s Research,Hospital in Memphis, TN, May ... Fraternity, Inc., has taken on the,awesome responsibility of sponsoring ...
... 7 /PRNewswire-FirstCall/ - NUCRYST Pharmaceuticals,a developer and manufacturer ... announced the appointment of David B. Holtz as ... 2008. In these,roles, Mr. Holtz will be responsible ... and Information Technology reporting to,Thomas E. Gardner, Chairman ...
Cached Medicine News:Health News:UCSF receives funding for building from California stem cell agency 2Health News:UCSF receives funding for building from California stem cell agency 3Health News:USC receives nearly $27 million in funding for new stem cell research facility 2Health News:UAB first in US to offer speedier precise cancer radiotherapy 2Health News:Nektar Therapeutics Announces First Quarter 2008 Results 2Health News:Nektar Therapeutics Announces First Quarter 2008 Results 3Health News:Nektar Therapeutics Announces First Quarter 2008 Results 4Health News:Nektar Therapeutics Announces First Quarter 2008 Results 5Health News:Nektar Therapeutics Announces First Quarter 2008 Results 6Health News:Nektar Therapeutics Announces First Quarter 2008 Results 7Health News:Nektar Therapeutics Announces First Quarter 2008 Results 8Health News:Kappa Alpha Psi Fraternity Celebrates St. Jude Partnership 2Health News:Kappa Alpha Psi Fraternity Celebrates St. Jude Partnership 3Health News:NUCRYST Appoints David B. Holtz as Vice President and Chief Financial Officer 2Health News:NUCRYST Appoints David B. Holtz as Vice President and Chief Financial Officer 3Health News:NUCRYST Appoints David B. Holtz as Vice President and Chief Financial Officer 4
(Date:6/18/2013)... 2013 New-generation electronic designs are focused ... lightweight. Simultaneously, circuitry is increasing the number of ... which it performs at. Connecting cables from the ... equipment, such as cameras or detectors, must be ... connectors include custom cable designs for high-quality signal ...
(Date:6/18/2013)... EMERYVILLE, Calif. , June 18, 2013 ... today from a Phase 2/3 clinical trial of ... statistically significant improvement in levodopa-induced dyskinesia (LID) as ... versus placebo in the Unified Dyskinesia Rating Scale ... amantadine intended for once-nightly administration that is being ...
(Date:6/18/2013)... 2013   Polymer Technology Systems, Inc. ... Group to integrate the CardioChek ® ... by health systems across the country. The CardioChek ... distributed through Hanson Medical Systems , offers ... LDL cholesterol, triglycerides, and glucose. (Logo: ...
Breaking Medicine Technology:Omnetics Circular Connectors Offer Both Micro and Nano Interconnects for Highly Portable Electronic Systems, Meeting the Needs of Designers Looking for Size Reduction Options and Cable Flexibility 2Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 2Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 3Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 4Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 5Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 6Polymer Technology Systems, Inc. to Provide Point-of-Care Lipid Testing to Aegis Health Group's Hospital Clients 2Polymer Technology Systems, Inc. to Provide Point-of-Care Lipid Testing to Aegis Health Group's Hospital Clients 3
... /PRNewswire-Asia/ -- Neusoft Corporation ("Neusoft", 600718.SH), a leading ... announced that its wholly-owned subsidiary Neusoft Europe Inc. ... Aerotel Medical Systems Ltd. ("Aerotel"), a leading global ... and telecare solutions based in Israel, under which ...
... Leading events organiser UBM Live is today ... ICSE, P-MEC and BioPh Japan events in Tokyo as a ... have now been rescheduled and will be held from 13-15 ... business community is intent on picking itself up as quickly ...
Cached Medicine Technology:Neusoft to Invest in Israeli Medical Solutions Company for Accelerating Expansion in Global Healthcare Service Market 2Boost For Japanese Pharma Market as UBM Announces Rescheduled Japan Pharma and Bio Events 2Boost For Japanese Pharma Market as UBM Announces Rescheduled Japan Pharma and Bio Events 3
The Linvatec 3mm and 5mm Universal Light Guides are autoclavable. They offer flexibility, superior light transmission, and universal fittings in a lightweight package....
ACMI™ offers an assortment of fiberoptic light guides, high transmission autoclavable fiberoptic light guides, and light guide adapters to connect our scopes to other manufacturers' light sourc...
ACMI™ offers an assortment of fiberoptic light guides, high transmission autoclavable fiberoptic light guides, and light guide adapters to connect our scopes to other manufacturers' light sourc...
... EndoEYE offers a revolutionary ... places a miniaturized CCD chip ... making fragile rod lenses a ... puts your eye right at ...
Medicine Products: